Label Changes for:
Bicnu (carmustine) for injection
March 2011
Changes have been made to the PRECAUTIONS and ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – March 2011
PRECAUTIONS
Drug Interactions
- Greater myelotoxicity (e.g., leukopenia and neutropenia) have been reported when carmustine was combined with cimetidine.
ADVERSE REACTIONS
Hematologic Toxicity
- Greater myelotoxicity (e.g., leukopenia and neutropenia) has been reported when carmustine was combined with cimetidine.
